Prospective, Randomized, Open Label, Blinded-Endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM [ambulatory blood pressure monitoring] in Subjects With Mild-to-Moderate Essential Hypertension.

Trial Profile

Prospective, Randomized, Open Label, Blinded-Endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM [ambulatory blood pressure monitoring] in Subjects With Mild-to-Moderate Essential Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2009

At a glance

  • Drugs Ramipril (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms HYCCRA
  • Most Recent Events

    • 10 Sep 2009 Actual patient number changed from 115 to 120 as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Results published in Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top